Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
This observational tissue analysis links immune-cell topography to pembrolizumab response in14selected lymphoma patients from an earlier24-patient trial. Seventy regions and large cell counts remain nested within those patients. Assay validation and resampling reuse the same cohort, without an independent clinical test. Several abundance and signature measures were null; the proposed chemokine mechanism is not causally demonstrated. Nolan is a corresponding coauthor/joint supervisor. Published government grants and commercial/patent disclosures remain attributed, without establishing a classified approach or UAP programme.
Complete specialist supplied XML text; native graphics unreviewed